Keywords: merlion, sankyo, sign, drug, deal, privately-held, singapore-based
MerLion and Sankyo sign drug R&D deal
Article | 22 April 2005
Privately-held Singapore-based MerLion Pharmaceuticals says it has agreed to a three-year drug discovery and development collaboration with Japanese drugmaker Sankyo.
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Is the diabetes market facing a blockbuster-free future?
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
